Search

Iptacopan

[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor

Aficamten

[L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and … Aficamten is a cardiac myosin inhibitor.

Serdexmethylphenidate

[A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma … [A230698, A230703] The underlying cause of ADHD is unclear but likely involves dysfunction in dopaminergic and noradrenergic neurotransmission, as evidenced by the clear beneficial effect of CNS stimulants

Ferrous bisglycinate

It is found in foods for food enrichment or in supplements for the treatment of iron deficiency or iron deficiency anemia. … Ferrous bisglycinate is a chelate that is used as a source of dietary iron.

VL-2397

Encainide

The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. … Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.

Mazindol

Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity. … Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than [amphetamine], but with some similar side effects.

Vilanterol

[A7737] This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). … with the (R)-configuration.

Icaridin

Icaridin is reported to be less irritating than [Diethyltoluamide], another common insect repellant, and products containing up to 20% of icaridin are considered safe for long-term use in adults [A39231 … Icaridin has been commonly used as a topically-applied insect repellent in various countries but was officially licensed for use in the United States in 2001 and Canada in 2012 [L4595].

Entecavir

Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine … It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.